오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - sotalol hydrochloride, quantity: 160 mg - tablet, uncoated - excipient ingredients: stearic acid; lactose; indigo carmine; microcrystalline cellulose; magnesium stearate; maize starch; colloidal anhydrous silica - solavert is indicated for use in the prevention and treatment of supraventricular and ventricular arrhythmias.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - sotalol hydrochloride, quantity: 80 mg - tablet, uncoated - excipient ingredients: colloidal anhydrous silica; microcrystalline cellulose; stearic acid; indigo carmine; lactose; magnesium stearate; maize starch - solavert is indicated for use in the prevention and treatment of supraventricular and ventricular arrhythmias.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - sotalol hydrochloride, quantity: 160 mg - tablet, uncoated - excipient ingredients: magnesium stearate; methylcellulose; dextrates; colloidal anhydrous silica; indigo carmine aluminium lake - prevention and treatment of supraventricular and ventricular arrhythmias.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - sotalol hydrochloride, quantity: 160 mg - tablet, uncoated - excipient ingredients: magnesium stearate; stearic acid; indigo carmine; maize starch; colloidal anhydrous silica; microcrystalline cellulose; lactose - sotacor is indicated for use in the prevention and treatment of supraventricular and ventricular arrhythmias.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - sotalol hydrochloride, quantity: 80 mg - tablet, uncoated - excipient ingredients: lactose; microcrystalline cellulose; indigo carmine; maize starch; colloidal anhydrous silica; magnesium stearate; stearic acid - sotacor is indicated for use in the prevention and treatment of supraventricular and ventricular arrhythmias.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - sotalol hydrochloride, quantity: 160 mg - tablet, uncoated - excipient ingredients: maize starch; sodium starch glycollate; purified talc; magnesium stearate; calcium hydrogen phosphate; povidone - for the prevention and treatment of supraventricular and ventricular arrhythmias.

영국 - 영어 - MHRA (Medicines & Healthcare Products Regulatory Agency)

arrow generics ltd - sotalol hydrochloride - oral tablet - 160mg

영국 - 영어 - MHRA (Medicines & Healthcare Products Regulatory Agency)

de pharmaceuticals - sotalol hydrochloride - oral tablet - 40mg

미국 - 영어 - NLM (National Library of Medicine)

mutual pharmaceutical - sotalol (unii: a6d97u294i) (sotalol - unii:a6d97u294i) - tablet - 80 mg - sotalol hydrochloride tablets (af) are indicated for the maintenance of normal sinus rhythm [delay in time to recurrence of atrial fibrillation/atrial flutter (afib/afl)] in patients with symptomatic afib/afl who are currently in sinus rhythm. because sotalol hydrochloride tablets (af) can cause life-threatening ventricular arrhythmias, it should be reserved for patients in whom afib/afl is highly symptomatic. patients with paroxysmal afib/afl that is easily reversed (by valsalva maneuver, for example) should usually not be given sotalol hydrochloride tablets (af) (see warnings ). in general, antiarrhythmic therapy for afib/afl aims to prolong the time in normal sinus rhythm. recurrence is expected in some patients (see clinical studies ). sotalol is also indicated for the treatment of documented life-threatening ventricular arrhythmias and is marketed under the brand name betapace® (sotalol hydrochloride). betapace® , however, must not be substituted for sotalol hydrochloride tablets (af) because of signifi

영국 - 영어 - MHRA (Medicines & Healthcare Products Regulatory Agency)

teva uk ltd - sotalol hydrochloride - oral tablet - 80mg